Multifocal motor neuropathy
Other Names for this Disease
- Multifocal motor neuropathy with conduction block
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
On this page
Multifocal motor neuropathy (MMN) is considered treatable with intravenous immune globulin (IVIG). Early treatment shortly after symptoms begin is recommended. Most people have a fairly rapid improvement in weakness with IVIG, but the improvement generally does not last beyond a few months. Maintenance IVIG infusions are usually needed every two to six weeks. For those with severe disease whose symptoms don't respond to IVIG (or for those who become resistant), treatment options are limited. Several reports have suggested that cyclophosphamide may be partially effective.
Last updated: 3/7/2016
- MMN Overview. GBS/CIDP Foundation International. 2016; http://www.gbs-cidp.org/variants/mmn-overview/.
- Lange D, Robinson-Papp J. Multifocal motor neuropathy. UpToDate. Waltham, MA: UpToDate; February, 2016;
- Finding Treatment Information - A video developed by GARD Information Specialists that explains how you can find information about treatment for a rare disease.
- The National Guideline Clearinghouse (NGC) is a public resource for evidence-based clinical practice guidelines. The NGC was originally created by the Agency for Healthcare Research and Quality (AHRQ) in partnership with the American Medical Association and the American Association of Health Plans.
- ClinicalTrials.gov lists trials that are studying or have studied Multifocal motor neuropathy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.